How Build Back Better Would Affect Drug Costs

This chart shows the implementation timeline of key provisions in the Build Back Better Act.

On November 19, 2021, the House of Representatives passed H.R. 5376, the Build Back Better Act (BBBA), which includes a broad package of health, social, and environmental proposals supported by President Biden. The BBBA includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers.

The provisions would allow the federal government to negotiate prices for some high-cost drugs covered under Medicare; require inflation rebates to limit annual increases in drug prices in Medicare and private insurance; cap out-of-pocket spending for Medicare Part D enrollees along with other Part D benefit changes; limit monthly copays for insulin to $35 for people with Medicare and private insurance; improve coverage of adult vaccines in Medicare, Medicaid, and CHIP; and repeal the Trump Administration’s drug rebate rule.

These provisions would take effect over the next several years, beginning in 2023. The BBBA, including these provisions, may be modified as the Senate considers the legislation.


Explaining the Prescription Drug Provisions in the Build Back Better Act

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.